BioStar Capital | Activity

Milestone

Two-year proximal neck dynamics data was presented from the first-in-human study of Nectero's abdominal aortic aneurysm treatment.

Nectero Medical

Nectero Medical BioStar Capital

globenewswire.comJUN 25, 2026

JUN 25, 2026

Exit

Stryker completed its acquisition of portfolio company Amplitude Vascular Systems (AVS) in a deal worth up to $835M, adding next-generation IVL technology to its peripheral vascular portfolio.

Amplitude Vascular Systems

Amplitude Vascular Systems BioStar Capital

globenewswire.comMAY 7, 2026 businesswire.com globenewswire.com

MAY 7, 2026

Milestone

MMI's Symani Surgical System treated its first Alzheimer's patient in the REMIND study.

Micro Medical Instruments

Micro Medical Instruments BioStar Capital

globenewswire.comMAY 4, 2026

MAY 4, 2026

Milestone

Nectero reported two-year safety and efficacy data from a first-in-human trial for small- to medium-sized abdominal aortic aneurysms.

Nectero Medical

Nectero Medical BioStar Capital

globenewswire.comAPR 23, 2026

APR 23, 2026

Milestone

MMI won FDA clearance and completed the first U.S. clinical use of its robotic microsurgical dissection instruments with Symani.

Micro Medical Instruments

Micro Medical Instruments BioStar Capital

globenewswire.comDEC 9, 2025 globenewswire.com

DEC 9, 2025

Milestone

MMI received IDE approval from the FDA for the first robotic microsurgical study in Alzheimer's patients.

Micro Medical Instruments

Micro Medical Instruments BioStar Capital

globenewswire.comNOV 5, 2025

NOV 5, 2025

Milestone

AVS announced positive safety and effectiveness data in the first 95 patients treated in its Pulse IVL IDE study.

Amplitude Vascular Systems

Amplitude Vascular Systems BioStar Capital

businesswire.comNOV 4, 2025

NOV 4, 2025

Milestone

MMI completed the world's first robotic microsurgical intracranial brain surgery.

Micro Medical Instruments

Micro Medical Instruments BioStar Capital

globenewswire.comOCT 6, 2025

OCT 6, 2025

Investment

Participated in Versa Vascular's oversubscribed $27.3M Series C, which also saw David Hovda appointed CEO.

Versa Vascular

Versa Vascular BioStar Capital

s3vc.comSEP 18, 2025

SEP 18, 2025

Milestone

Nectero secured Category III CPT codes for its investigational AAA therapy.

Nectero Medical

Nectero Medical BioStar Capital

globenewswire.comJUN 12, 2025

JUN 12, 2025

Milestone

Foldax secured approval for its TRIA mitral heart valve in India.

Foldax

Foldax BioStar Capital

businesswire.comJUN 5, 2025

JUN 5, 2025

Investment

Participated in AVS's $36M Series B financing ahead of its U.S. commercial IVL launch.

Amplitude Vascular Systems

Amplitude Vascular Systems BioStar Capital

businesswire.comJAN 28, 2025

JAN 28, 2025

Exit

Portfolio company V-Wave, a heart-failure device maker, was acquired by Johnson & Johnson in a deal worth up to $1.7B.

V-Wave

V-Wave BioStar Capital

businesswire.comAUG 20, 2024

AUG 20, 2024

Investment

Participated in Nectero Medical's $96M Series D financing for its endovascular AAA stabilization therapy.

Nectero Medical

Nectero Medical BioStar Capital

businesswire.comAPR 11, 2024

APR 11, 2024

BioStar Capital Activity

Two-year proximal neck dynamics data was presented from the first-in-human study of Nectero's abdominal aortic aneurysm treatment.

Stryker completed its acquisition of portfolio company Amplitude Vascular Systems (AVS) in a deal worth up to $835M, adding next-generation IVL technology to its peripheral vascular portfolio.

MMI's Symani Surgical System treated its first Alzheimer's patient in the REMIND study.

Nectero reported two-year safety and efficacy data from a first-in-human trial for small- to medium-sized abdominal aortic aneurysms.

MMI won FDA clearance and completed the first U.S. clinical use of its robotic microsurgical dissection instruments with Symani.

MMI received IDE approval from the FDA for the first robotic microsurgical study in Alzheimer's patients.

AVS announced positive safety and effectiveness data in the first 95 patients treated in its Pulse IVL IDE study.

MMI completed the world's first robotic microsurgical intracranial brain surgery.

Participated in Versa Vascular's oversubscribed $27.3M Series C, which also saw David Hovda appointed CEO.

Nectero secured Category III CPT codes for its investigational AAA therapy.

Foldax secured approval for its TRIA mitral heart valve in India.

Participated in AVS's $36M Series B financing ahead of its U.S. commercial IVL launch.

Portfolio company V-Wave, a heart-failure device maker, was acquired by Johnson & Johnson in a deal worth up to $1.7B.

Participated in Nectero Medical's $96M Series D financing for its endovascular AAA stabilization therapy.